Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2009
03/26/2009WO2009016577A3 A pharmaceutical composition comprising atorvastatin and niacin
03/26/2009WO2009016564A3 2-aza-bicyclo[3.3.0]octane derivatives
03/26/2009WO2009016560A3 Trans-3-aza-bicyclo[3.1.0]hexane derivatives
03/26/2009WO2009016462A3 Substituted bicyclolactam compounds
03/26/2009WO2009016460A3 Pyrazole compounds and their use as raf inhibitors
03/26/2009WO2009016253A3 Cyanomethyl substituted n-acyl tryptamines
03/26/2009WO2009015368A3 Multikinase inhibitors for use in the treatment of cancer
03/26/2009WO2009015274A3 Polyethylene based bioactive agents
03/26/2009WO2009015214A3 Nanoparticles for imaging and treating chlamydial infection
03/26/2009WO2009015014A3 Multi-step method of pain and/or inflammation treatment
03/26/2009WO2009013433A3 Use of pactimibe for the preparation of a drug intended to prevent or treat a disease caused by a sebaceous gland dysfunction in humans or animals
03/26/2009WO2009011901A3 Methods for promoting wakefulness
03/26/2009WO2009011795A3 Methods for treating stress induced emotional disorders
03/26/2009WO2009009793A3 Inhibitors of akt/pkb with anti-tumor activity
03/26/2009WO2009009768A3 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS
03/26/2009WO2009009040A3 Fatty acid compositions and methods of use
03/26/2009WO2009007753A3 4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer
03/26/2009WO2009007457A3 Compounds and methods for modulating rho gtpases
03/26/2009WO2009006389A8 Pyrimidine derivatives useful as raf kinase inhibitors
03/26/2009WO2009004188A3 Direct dissolution of docetaxel in a solvent in polysorbate 80
03/26/2009WO2008157614A9 Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
03/26/2009WO2008153884A8 Compositions useful for treating gastroesophageal reflux disease
03/26/2009WO2008151235A3 Compositions for delivering medicaments into the lungs, uses thereof
03/26/2009WO2008151119A3 Compositions and methods for use of scar tissue in repair of weight bearing surfaces
03/26/2009WO2008145838A3 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of cranial traumas
03/26/2009WO2008145688A3 Pyrrolopyridine compounds, process for their preparation, and their use as medicaments
03/26/2009WO2008141731A3 Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
03/26/2009WO2008140571A3 Methods and compositions for treating influenza
03/26/2009WO2008139288A3 Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials
03/26/2009WO2008137780A3 Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
03/26/2009WO2008135791A8 Imidazoquinolines with immuno-modulating properties
03/26/2009WO2008132155A3 Inhibitors of the binding between hdm2 and the proteasome
03/26/2009WO2008126943A3 Method for manufacturing neuraminic acid derivatives
03/26/2009WO2008118879A3 Antiviral compositions comprising 2 compounds
03/26/2009WO2008116641A3 Oleyl phosphocholine
03/26/2009WO2008109490A4 Nucleic acid compounds for inhibiting chek1 gene expression and uses thereof
03/26/2009WO2008109378A4 Nucleic acid compounds for inhibiting pdgfr gene expression and uses thereof
03/26/2009WO2008106058A3 Inhibitors of serine proteases
03/26/2009WO2008104852A3 Pharmaceutical compositions comprising adsorbate of fenofibrate
03/26/2009WO2008094617A3 Crystalline forms of deferasirox
03/26/2009WO2008076243A3 Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
03/26/2009WO2008073318A3 Use of atp in controlled regional reperfusion as treatment during acute myocardial infarction
03/26/2009WO2008073193A3 Ocular devices and methods of making and using thereof
03/26/2009WO2008058897A3 Diphyllin and other lignans as a medicament for v-atpase mediated disease
03/26/2009WO2008058269A3 Compounds and methods for modulating protein trafficking
03/26/2009WO2008053374A3 Topically applied probucol-containing agent with protective and regenerative effect
03/26/2009WO2008042422A3 Bicyclic and tricyclic derivatives as thrombin receptor antagonists
03/26/2009WO2008039525A3 Cadherin antagonists in combination with anticancer agents for use in cancer treatment
03/26/2009WO2008032204A8 Substituted pyridylmethyl bicyclocarboxyamide compounds
03/26/2009WO2008017914A3 Topical antiacne preparations containing retinoid (tazarotene or adapalene), antibiotic (clindamycin phosphate) and/or keratolytic (miscrosponged benzoyl peroxide)
03/26/2009WO2008015680A3 Polycyclic dianthraquinones as inhibitors of inflammatory cytokines
03/26/2009WO2008007211A8 Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
03/26/2009WO2008005194A4 Method for the eradication of pathogens comprising generating molecular iodine in situ
03/26/2009WO2007112287A3 Hme transdermal compositions containing testosterone
03/26/2009WO2007092620A3 Stable formulations, and methods of their preparation and use
03/26/2009WO2006009568A3 Peripherally-acting vasodilators
03/26/2009WO2006004722A3 Compositions and methods for selectively activating human sirtuins
03/26/2009WO2006002073A3 Method for preventing heme-induced lipid peroxidation
03/26/2009WO2005084295A3 Fused heterotricyclic compounds as inhibitors of 17b-hydroxysteroid dehydrogenase 3
03/26/2009WO2005044977A3 Compositions, splice variants and methods relating to lung specific genes and proteins
03/26/2009WO2005044802A3 Tetrahydro-quinolinylurea derivatives as vrl antagonists
03/26/2009WO2005018486A3 Use of melatonin-containing oral supplement with animals
03/26/2009WO2005011604A3 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
03/26/2009WO2003070158A3 Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
03/26/2009US20090082855 Coating for controlled release of a therapeutic agent
03/26/2009US20090082738 Natural Anti-Inflammatory Agents for Reducing Pain
03/26/2009US20090082567 2,4-pyrimidinediamine compounds and their uses
03/26/2009US20090082473 Composition comprising resveratol and its topical use thereof for reducing human hair growth
03/26/2009US20090082471 Deuterium-enriched fingolimod
03/26/2009US20090082470 Stat3 inhibiting compositions and methods
03/26/2009US20090082469 Deuterium-enriched terbinafine
03/26/2009US20090082468 Deuterium-enriched levalbuterol
03/26/2009US20090082467 Treatment of migraine headaches using antiestrogens
03/26/2009US20090082466 Solid oral dosage forms of opioid agonist painkiller, one or more of polyethylene glycol mono- or distearates, water insoluble waxes, glycerol monostearate or hydrogenated vegetable oil; tamper resistant dosage form; prevent or minimizing excessive peak concentrations when taken with alcohol
03/26/2009US20090082465 Deuterium-enriched lisdexamfetamine
03/26/2009US20090082464 Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
03/26/2009US20090082463 N-substituted phenylacetamide derivative and pharmaceutical composition containing the same
03/26/2009US20090082462 Deuterium-enriched armodafinil
03/26/2009US20090082461 Deuterium-enriched modafinil
03/26/2009US20090082459 Deuterium-enriched guanfacine
03/26/2009US20090082458 Deuterium-enriched aliskiren
03/26/2009US20090082457 (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis
03/26/2009US20090082456 Soluble epoxide hydrolase inhibitors
03/26/2009US20090082455 Therapeutic agent for ophthalmic disease
03/26/2009US20090082454 Deuterium-enriched disufenton
03/26/2009US20090082452 Deuterium-enriched lumiracoxib
03/26/2009US20090082451 Use of thyroid hormone conversion inhibitors
03/26/2009US20090082450 Deuterium-enriched diclofenac
03/26/2009US20090082449 Spray-Drying Process for Producing a Dry Caritine Powder or Granulate
03/26/2009US20090082448 Method for placental exfoliation using oxo-arachidonic acid or the like
03/26/2009US20090082447 Pharmaceutical Compositions Containing Omega 3 Fatty Acids
03/26/2009US20090082446 Use of Hydroxyoleic acid and related compounds in the manufacture of drugs
03/26/2009US20090082445 Gossypol co-crystals and the use thereof
03/26/2009US20090082444 Compositions for the Treatment of Blood Disorders
03/26/2009US20090082442 Deuterium-enriched lubiprostone
03/26/2009US20090082441 Deuterium-enriched tesaglitazar
03/26/2009US20090082440 Simple pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
03/26/2009US20090082438 Coordination Compound Composed of Diaminocyclohexane Platinum (II) and Block Copolymer and Anti-Cancer Agent Comprising the Same
03/26/2009US20090082437 Use of Oxaliplatin for Enhancing Radiosensitivity in Radiotherapy of Cervical Cancer
03/26/2009US20090082436 Deuterium-enriched rivastigmine